ENG
Acute Lymphocytic Leukemia Therapeutics Market: Global Industry Analysis and Forecast (2024-2030) by Therapy, Type, and Region
The Acute Lymphocytic Leukemia Therapeutics Market size was valued at US$ 3.28 Billion in 2023 and the Acute Lymphocytic Leukemia Therapeutics revenue is expected to grow at 4.1% through 2024 to 2030, reaching nearly US$ 4.35
Billion.
Format : PDF | Report ID : SMR_281
Acute Lymphocytic Leukemia Therapeutics Market Definition & Overview:
The increased incidence of acute lymphoblastic leukaemia (ALL) over the world is one of the primary factors driving this market's growth. Each year, around 1.7 per 100,000 men and women are diagnosed with the disease. According to the American Cancer Institute, there will be roughly 5,930 new cases of ALL in 2019, including 3,280 men and 2,650 females. Also, it is anticipated that the number of cases of ALL in Asia-Pacific and South American countries would vary from 0.4 to 2 per 100,000 by 2020. Sement analysis of report on the Acute Lymphocytic Leukemia Therapeutics Market is provided by therapy, type and region.
To get more Insights: Request Free Sample Report
Acute Lymphocytic Leukemia Therapeutics Market Dynamics:
The global acute lymphocytic leukemia therapeutics market is expected to grow due to increased government and pharmaceutical organization activities to raise awareness about the condition. Secondly, the market is expected to grow due to developments in technology for treating illnesses that have been induced by increased expenditures made by manufacturers.
The introduction of new pharmaceuticals for acute lymphocytic leukemia therapeutics, as well as technology improvements in the healthcare sector, are expected to boost the growth of the acute lymphocytic leukemia therapeutics market during the forecast period. Besides that, the "Therapeutically Applicable Research to Generate Effective Treatments (TARGET)" initiative and the "Childhood Cancer Targeted Therapeutics Workshop" has introduced several programs and collaborated with several research groups from around the world, including St. Jude Children's Research Hospital and the University of New Mexico, to provide patients with early diagnosis and better leukaemia treatment. In the forecast period, these factors are expected to drive market growth.
Acute Lymphocytic Leukemia Therapeutics Market Segment Analysis:
By Therapy, Chemotherapy is expected to be the most popular type of treatment in the acute lymphocytic leukemia therapeutics market. Chemotherapy is the principal treatment for persons with acute lymphoblastic leukaemia (ALL), according to the American Cancer Society, and it comprises three phases: remission, consolidation, and maintenance. Chemotherapy is the employment of cytotoxic medicines to kill cancer cells.
Some of the medications used in ALL chemotherapy include amsacrine (NordMedica), cyclophosphamide (Baxter), and cytarabine (Pfizer). These medications are provided by global pharmaceutical companies such as Baxter International and Pfizer. According to a 2019 study by the Leukemia & Lymphoma Society, ALL is the most frequent malignancy in children, adolescents, and young people under the age of 20, accounting for 19.8% of all cancer diagnoses in this age range. As a result of the increased frequency of ALL, particularly among youngsters, the market for chemotherapy is likely to grow.
By Type, in the acute lymphocytic leukemia therapeutics market, hospital pharmacies held the biggest share. This is due to an increase in the number of patients who require treatment in hospitals with modern infrastructure and suitable amenities. In addition, the expanding number of hospitals, combined with acceptable reimbursement rules, is driving this market forward.
Acute Lymphocytic Leukemia Therapeutics Market Regional Insights:
Because of the increased number of occurrences of this illness in the region as a result of hereditary factors, environmental factors, and radiation, North America is likely to dominate this market. Additionally, the presence of multinational corporations, as well as good government regulations, well-established healthcare infrastructure, and favourable government policies make this area dominant in this sector.
During the forecast period, the Asia-Pacific Acute Lymphocytic Leukemia Therapeutics Market is expected to have the quickest CAGR of 6.3 per cent. In the Asia-Pacific region, China and India are likely to be the fastest-growing leukaemia markets. Increasing R&D investment, a huge pool of patients, and expanding government financing are some of the primary driving drivers for the leukaemia therapeutics market in emerging countries.
The objective of the report is to present a comprehensive analysis of the Acute Lymphocytic Leukemia Therapeutics Market to the stakeholders in the industry. The report provides trends that are most dominant in the Acute Lymphocytic Leukemia Therapeutics Market and how these trends will influence new business investments and market development throughout the forecast period. The report also aids in the comprehension of the ALLT market dynamics and competitive structure of the market by analyzing market leaders, market followers, and regional players.
The qualitative and quantitative data provided in the Acute Lymphocytic Leukemia Therapeutics Market report is to help understand which market segments, regions are expected to grow at higher rates, factors affecting the market, and key opportunity areas, which will drive the industry and market growth through the forecast period. The report also includes the competitive landscape of key players in the industry along with their recent developments in the Acute Lymphocytic Leukemia Therapeutics Market. The report studies factors such as company size, market share, market growth, revenue, production volume, and profits of the key players in the ALLT Market.
The report provides Porter's Five Force Model, which helps in designing the business strategies in the market. The report helps in identifying how many rivals are existing, who they are, and how their product quality is in the Market. The report also analyses if the Acute Lymphocytic Leukemia Therapeutics Market is easy for a new player to gain a foothold in the market, do they enter or exit the market regularly if the market is dominated by a few players, etc.
Acute Lymphocytic Leukemia Therapeutics Market Scope:
|
Acute Lymphocytic Leukemia Therapeutics Market |
|
|
Market Size in 2023 |
USD 3.28 Bn. |
|
Market Size in 2030 |
USD 4.35 Bn. |
|
CAGR (2024-2030) |
4.1% |
|
Historic Data |
2018-2022 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2030 |
|
Segment Scope |
by Therapy
|
|
By Type
|
|
|
Regional Scope |
North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America |
Acute Lymphocytic Leukemia Therapeutics Market Players:
- Erytech Pharma (France)
- Spectrum Pharmaceuticals, Inc. (United States)
- Pfizer, Inc. (United States)
- Sigma-Tau s.p.a. (Italy)
- Genzyme Corporation (United States)
- Amgen, Inc. (United States)
- Bristol-Myers Squibb Company (United States)
- Erytech Pharma (France)
- Leadiant Biosciences, Inc. (Italy)
- Novartis AG (Switzerland)
- Rare Disease Therapeutics, Inc. (United States)
- Sanofi (France)
- Spectrum Pharmaceuticals, Inc (United States)
- Takeda Pharmaceutical Company Limited. (Japan)
Frequently Asked Questions
The worldwide acute lymphocytic leukaemia therapeutics pharmaceuticals market is expected to grow due to increased government and pharmaceutical organization activities to raise awareness about the condition.
Because of the increased number of occurrences of this illness in the region as a result of hereditary factors, environmental factors, and radiation, North America is likely to dominate this market.
Increasing R&D investment, a huge pool of patients, and expanding government financing are some of the primary driving drivers for the leukaemia therapeutics market in the region.
Erytech Pharma, Spectrum Pharmaceuticals, Inc., Pfizer, Inc., Sigma-Tau s.p.a., Genzyme Corporation, and Amgen, Inc.
1. Research Methodology
1.1 Research Data
1.1.1. Primary Data
1.1.2. Secondary Data
1.2. Market Size Estimation
1.2.1. Bottom-Up Approach
1.2.2. Top-Up Approach
1.3. Market Breakdown and Data Triangulation
1.4. Research Assumption
2. Acute Lymphocytic Leukemia Therapeutics Market Executive Summary
2.1. Market Overview
2.2. Market Size (2023) and Forecast (2024 – 2030) and Y-O-Y%
2.3. Market Size (USD) and Market Share (%) – By Segments and Regions
3. Global Acute Lymphocytic Leukemia Therapeutics Market: Competitive Landscape
3.1. SMR Competition Matrix
3.2. Key Players Benchmarking
3.2.1. Company Name
3.2.2. Headquarter
3.2.3. Business Segment
3.2.4. End-user Segment
3.2.5. Y-O-Y%
3.2.6. Revenue (2023)
3.2.7. Company Locations
3.3. Market Structure
3.3.1. Market Leaders
3.3.2. Market Followers
3.3.3. Emerging Players
3.4. Consolidation of the Market
3.4.1. Strategic Initiatives and Developments
3.4.2. Mergers and Acquisitions
3.4.3. Collaborations and Partnerships
3.4.4. Product Launches and Innovations
4. Acute Lymphocytic Leukemia Therapeutics Market: Dynamics
4.1. Acute Lymphocytic Leukemia Therapeutics Market Trends by Region
4.1.1. North America
4.1.2. Europe
4.1.3. Asia Pacific
4.1.4. Middle East and Africa
4.1.5. South America
4.2. Acute Lymphocytic Leukemia Therapeutics Market Drivers
4.3. Acute Lymphocytic Leukemia Therapeutics Market Restraints
4.4. Acute Lymphocytic Leukemia Therapeutics Market Opportunities
4.5. Acute Lymphocytic Leukemia Therapeutics Market Challenges
4.6. PORTER’s Five Forces Analysis
4.6.1. Intensity of the Rivalry
4.6.2. Threat of New Entrants
4.6.3. Bargaining Power of Suppliers
4.6.4. Bargaining Power of Buyers
4.6.5. Threat of Substitutes
4.7. PESTLE Analysis
4.7.1. Political Factors
4.7.2. Economic Factors
4.7.3. Social Factors
4.7.4. Legal Factors
4.7.5. Environmental Factors
4.8. Technological Roadmap
4.9. Regulatory Landscape
4.9.1. Market Regulation by Region
4.9.1.1. North America
4.9.1.2. Europe
4.9.1.3. Asia Pacific
4.9.1.4. Middle East and Africa
4.9.1.5. South America
4.9.2. Impact of Regulations on Market Dynamics
4.9.3. Government Schemes and Initiatives
5. Acute Lymphocytic Leukemia Therapeutics Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
5.1. Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Therapy (2023-2030)
5.1.1. Chemotherapy
5.1.2. Hyper-CVAD
5.1.3. CALGB 8811 regimen
5.1.4. Linker regimen
5.1.5. Nucleoside Metabolic Inhibitors
5.1.6. Oncaspar
5.1.7. Targeted therapy
5.1.8. Radiation Therapy
5.1.9. Stem cell transplantation
5.2. Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Type (2023-2030)
5.2.1. Philadelphia chromosome
5.2.2. Precursor B-cell ALL
5.2.3. T-cell ALL
5.3. Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Region (2023-2030)
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. Middle East and Africa
5.3.5. South America
6. North America Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
6.1. North America Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Therapy (2023-2030)
6.1.1. Chemotherapy
6.1.2. Hyper-CVAD
6.1.3. CALGB 8811 regimen
6.1.4. Linker regimen
6.1.5. Nucleoside Metabolic Inhibitors
6.1.6. Oncaspar
6.1.7. Targeted therapy
6.1.8. Radiation Therapy
6.1.9. Stem cell transplantation
6.2. North America Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Type (2023-2030)
6.2.1. Philadelphia chromosome
6.2.2. Precursor B-cell ALL
6.2.3. T-cell ALL
6.3. North America Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Country (2023-2030)
6.3.1. United States
6.3.2. Canada
6.3.3. Mexico
7. Europe Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
7.1. Europe Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Therapy (2023-2030)
7.2. Europe Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Type (2023-2030)
7.3. Europe Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Country (2023-2030)
7.3.1. United Kingdom
7.3.2. France
7.3.3. Germany
7.3.4. Italy
7.3.5. Spain
7.3.6. Sweden
7.3.7. Austria
7.3.8. Rest of Europe
8. Asia Pacific Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
8.1. Asia Pacific Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Therapy (2023-2030)
8.2. Asia Pacific Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Type (2023-2030)
8.3. Asia Pacific Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Country (2023-2030)
8.3.1. China
8.3.2. S Korea
8.3.3. Japan
8.3.4. India
8.3.5. Australia
8.3.6. Indonesia
8.3.7. Malaysia
8.3.8. Vietnam
8.3.9. Taiwan
8.3.10. Rest of Asia Pacific
9. Middle East and Africa Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
9.1. Middle East and Africa Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Therapy (2023-2030)
9.2. Middle East and Africa Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Type (2023-2030)
9.3. Middle East and Africa Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Country (2023-2030)
9.3.1. South Africa
9.3.2. GCC
9.3.3. Nigeria
9.3.4. Rest of ME&A
10. South America Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
10.1. South America Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Therapy (2023-2030)
10.2. South America Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Type (2023-2030)
10.3. South America Acute Lymphocytic Leukemia Therapeutics Market Size and Forecast, by Country (2023-2030)
10.3.1. Brazil
10.3.2. Argentina
10.3.3. Rest Of South America
11. Company Profile: Key Players
11.1. Erytech Pharma (France)
11.1.1. Company Overview
11.1.2. Business Portfolio
11.1.2.1. Product Name
11.1.2.2. Product Details (Price, Features, etc)
11.1.3. Financial Overview
11.1.3.1. Total Revenue
11.1.3.2. Segment Revenue
11.1.3.3. Regional Revenue
11.1.4. SWOT Analysis
11.1.5. Strategic Analysis
11.1.6. Recent Developments
11.2. Spectrum Pharmaceuticals, Inc. (United States)
11.3. Pfizer, Inc. (United States)
11.4. Sigma-Tau s.p.a. (Italy)
11.5. Genzyme Corporation (United States)
11.6. Amgen, Inc. (United States)
11.7. Bristol-Myers Squibb Company (United States)
11.8. Erytech Pharma (France)
11.9. Leadiant Biosciences, Inc. (Italy)
11.10. Novartis AG (Switzerland)
11.11. Rare Disease Therapeutics, Inc. (United States)
11.12. Sanofi (France)
11.13. Spectrum Pharmaceuticals, Inc (United States)
11.14. Takeda Pharmaceutical Company Limited. (Japan)
12. Key Findings
13. Analyst Recommendations
13.1. Strategic Recommendations
13.2. Future Outlook
